856905-30-1

Upstream product

• 1085453-45-7 methyl 5-methyl-1-(4-methylbenzyl)-1H-pyrazole-3-carboxylate 
• 26177-51-5 (4-methylbenzyl)hydrazine dihydrochloride 
• 1085453-43-5 tert-butyl 2-isopropylidene-1-(4-methylbenzyl)hydrazine-carboxylate 
• 104-81-4 4-Methylbenzyl bromide 
• 4027-57-0 ethyl 5-methyl-2H-pyrazole-3-carboxylate 
• 51421-17-1 4-methylbenzylhydrazine 
• 20577-61-1 methyl 2,4-dioxopentanoate 

Downstream Products

• 1085451-10-0 2-[5-methyl-1-(4-methylbenzyl)-1H-pyrazol-3-yl]-5-phenyl-1,3-benzoxazole 
• 1085451-95-1 5-methyl-1-(4-methylbenzyl)-3-{4-[4-(trifluoromethoxy)phenyl]-1H-imidazol-2-yl}-1H-pyrazole 
• 1085454-08-5 N-[(1R)-2-hydroxy-1-phenylethyl]-5-methyl-1-(4-methyl-benzyl)-1H-pyrazole-3-carboxamide 
• 1085453-46-8 5-(5-methyl-1H-pyrazol-3-yl)-3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazole 
• 1085450-53-8 5-[5-methyl-1-(4-methylbenzyl)-1H-pyrazol-3-yl]-3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazole 
• 1085454-83-6 5-methyl-1-(4-methylbenzyl)-1H-pyrazole-3-carbonyl chloride 
• 1418296-83-9 2-({fluoro[5-methyl-1-(4-methylbenzyl)-1H-pyrazol-3-yl]methyl}sulphonyl)-1,3-benzothiazole 
• 1418297-36-5 2-fluoro-1-[5-methyl-1-(4-methylbenzyl)-1H-pyrazol-3-yl]-2-[4-(trifluoromethoxy)phenyl]ethanol 
• 1085454-04-1 5-methyl-1-(4-methylbenzyl)-1H-pyrazole-3-carbaldehyde 
• 1418297-39-8 1-[5-methyl-1-(4-methylbenzyl)-1H-pyrazol-3-yl]-2-[4-(trifluoromethoxy)-phenyl]ethane-1,2-dione 
• 1418297-40-1 2-hydroxy-1-[5-methyl-1-(4-methylbenzyl)-1H-pyrazol-3-yl]-2-[4-(trifluoromethoxy)phenyl]ethanone 
• 1437796-58-1 2-hydroxy-2-[5-methyl-1-(4-methylbenzyl)-1H-pyrazol-3-yl]-1-[4-(trifluoromethoxy)-phenyl]ethanone 
• 1418297-41-2 2-fluoro-1-[5-methyl-1-(4-methylbenzyl)-1H-pyrazol-3-yl]-2-[4-(trifluoromethoxy)phenyl]ethanone 
• 1418295-64-3 3-[(Z)-1-fluoro-2-{4-[(trifluoromethyl)sulphanyl]phenyl}vinyl]-5-methyl-1-(4-methylbenzyl)-1H-pyrazole 

Relevant academic research and scientific papers

PROCESS AND INTERMEDIATES FOR PREPARING BENZOXAZEPINES

Disclosed is a new process and intermediates for preparing benzoxazepines of Formula (I): (I) wherein Q is, and A, L, B, RA and m are as defined herein.

Inhibition of hypoxia-induced gene transcription by substituted pyrazolyl oxadiazoles: Initial lead generation and structure-activity relationships

The transcription factors hypoxia-inducible factor-1 and -2 (HIF-1 and HIF-2) orchestrate a multitude of processes that allow tumor cells to survive under conditions of low oxygen and nutrients, and that lead to resistance to some apoptotic pathways and facilitate invasion and metastasis. Therefore, inhibition of transactivation by HIF has become an attractive target in cancer research. Herein we present the results of a cell-based screening approach that led to the discovery of substituted 1H-pyrazole-3-carboxamides. Chemical optimization of the hit class with respect to potency and metabolic stability is described; it resulted in novel 5-(1H-pyrazol-3-yl)-1,2,4-oxadiazoles that inhibit the hypoxia-induced accumulation of HIF-1α and HIF-2α. The HIF inhibitory potency in the screening cell system was improved from IC 50 190 to 0.7 nM, and significant parts of the SAR are disclosed. For a key compound, the ability to suppress the hypoxia-induced expression of HIF target genes was studied in A549 human lung adenocarcinoma cells. The same compound shows a favorable pharmacokinetic profile in rats after i.v. and p.o. administration. Suppressing HIF target genes: Substituted 5-(1H-pyrazol-3-yl)-1, 2,4-oxadiazoles are presented as a novel chemotype to specifically inhibit the hypoxia-induced transcription of target genes of the transcription factor hypoxia-inducible factor (HIF). The new chemotype was derived from 1H-pyrazole-3-carboxamides that had been discovered from a cell-based screen. We present the optimization of the potency and metabolic stability of the initial screening hit. Copyright

HETEROCYCLIC AMIDES AS KINASE INHIBITORS

Disclosed are compounds having the formula (I) wherein X, Y, Z1, Z2, Z3, Z4, R5, RA, m, A. L, and B are as defined herein, and methods of making and using the same.

3-(Fluorovinyl)pyrazoles and their use

The present application relates to novel 3-(fluorovinyl)pyrazole derivatives, to processes for their preparation, to their use for treatment and/or prevention of diseases and to their use for the preparation of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of hyperproliferative and angiogenic diseases and those diseases which arise from metabolic adaptation to hypoxic states. Such treatments can be carried out as monotherapy or also in combination with other medicaments or further therapeutic measures.

HETEROARYL SUBSTITUTED PYRAZOLE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS

This invention relates to novel heteroaryl substituted pyrazole compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients or therapeutic measures.